EUVIMEDEUVIMED entdecken
Crossref

Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy

Qian-He Xu, Xiu-Yuan Yin, Zhen-Qiang Chen, En-Kui Huang, Xiaojun Yao, Xingguang Li, Pei-Nian Liu iD

Small · 2025

DOI: 10.1002/smll.202500015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Qian-He Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Functional Materials Chemistry, Key Laboratory for Advanced Materials, School of Chemistry and Molecular Engineering, East…. Hauptthemen laut MEDLINE: Immunotherapy, Cancer Vaccines, Melanoma, Needles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Macao Science and Technology Development Fund, Fundo para o Desenvolvimento das Ciências e da Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In situ personalized tumor vaccines are produced directly at the primary tumor site by killing cancer cells and stimulating immune cells, they are effective against individuals and bypass the complexity and high cost of in vitro vaccine production. However, their clinical application is hindered by insufficient efficiency in inducing immunogenic cancer cell death (ICD) and systemic inflammation caused by immune adjuvants. Here, personalized cancer vaccines are constructed in situ for melanoma immunotherapy based on bioorthogonal catalytic microneedles, which enable the catalytic release of prodrugs at tumor sites and mediate strong ICD and an enhanced tumor immune response while avoiding systemic immune storms and toxic side effects. By incorporating TiO 2 nanosheets supported Pd into swellable microneedles, the bioorthogonal microneedles are constructed to catalyze the depropargylation reaction of doxorubicin (DOX) prodrug and imiquimod (IMQ) prodrug in situ. The activated DOX at subcutaneous tumor sites induced strong ICD and released tumor‐associated antigens. Concurrently, the activated IMQ acts as a Toll‐like receptor (TLR7) agonist, enhancing the anti‐tumor immune response. In vivo experiments demonstrate that this immunotherapy achieves ≈97% inhibition of primary tumors and effectively inhibits untreated distant tumors (≈94% inhibition) and lung metastasis (≈92% inhibition).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyCancer VaccinesMelanomaNeedlesPrecision MedicineAnimalsImiquimodDoxorubicinMiceCell Line, TumorHumansProdrugsCatalysisMice, Inbred C57BL

Stichwörter der Autor:innen

bioorthogonal catalysiscancer immunotherapycancer vaccinesimmunogenic cell deathmicroneedle

Substanzen

Cancer VaccinesImiquimodDoxorubicinProdrugs

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Functional Materials Chemistry, Key Laboratory for Advanced Materials, School of Chemistry and Molecular Engineering, East China University of Science & Technology, Shanghai, 200237, China.
  • Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, 999078, China.
  • State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

ORCID-Profile: Pei-Nian Liu

Förderung

  • National Natural Science Foundation of China
  • Macao Science and Technology Development Fund
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia

Zitieren

APA

Xu, Q. H., Yin, X. Y., Chen, Z. Q., Huang, E. K., Yao, X., Li, X., & Liu, P. N. (2025). Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy. Small. https://doi.org/10.1002/smll.202500015

Vancouver

Xu QH, Yin XY, Chen ZQ, Huang EK, Yao X, Li X, et al. Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy. Small. 2025. doi:10.1002/smll.202500015

BibTeX
@article{Xu2025,
  author = {Xu, Qian-He and Yin, Xiu-Yuan and Chen, Zhen-Qiang and Huang, En-Kui and Yao, Xiaojun and Li, Xingguang and Liu, Pei-Nian},
  title = {Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202500015}
}
Kostenlos starten →